|Molecular Weight||158.16 g/mol|
|Synonyms||Hydroxypiracetam, 4-Hydroxy-2-oxopyrrolidine-N-acetamide, 62613-82-5, Neuractiv, Neuromet, ISF 2522, 4-Hydroxypiracetam|
|Application||Oxiracetam is a more potent derivative of the nootropic drug piracetam.|
|Appearance||White or Off-White Powder|
|Solubility||Soluble to 5 mM in Ethanol, Freely soluble in Water.|
|Storage||Store at room temperature or cooler, in a sealed airtight container, protected from heat, light and humidity.|
|Stability||Stable for at least two years when stored as above.|
Oxiracetam (4-hydroxy-2-oxo-pyrrolidinoacetamide) is a Nootropic compound of the pyrrolidinone class, based on Piracetam and developed as a stronger derivative. Oxiracetam is of interest to individuals and institutions involved in neuroscience studies and in research related to neuroprotection, especially from cognitive impairment.
Oxiracetam has an added 4-hydroxl group, when compared to Piracetam. Studies have shown that the hydroxyl group improves the availability and efficacy of this compound, when compared to Piracetam. As an example, clinical studies using Oxiracetam tend to administer doses of up to 25 mg/kg/day, while clinical studies using Piracetam administer doses up to 300mg/kg/day.
Oxiracetam is a GABA analogue that improves neuronal cell metabolism, increases the sensitivity and activity of AMPA receptors, and improves glutamate release with a greater efficacy than Piracetam. Clinical applications of Oxiracetam include beneficial effects on cognition – including spatial orientation, logical processing, concentration, focus, attenetion, and long-term potentiatation. Most clinical studies were performed on patients suffering from ADHD or mild to moderate dementia.
Animal studies have shown that Oxiracetam has a potent and reliable ability to prevent memory loss at an injected dosage range of between 3-30mg/kg. Furthermore, Oxiracetam has been suggested to assist with improving memory formation in otherwise healthy rats and mice, after a minimum five-day loading period.
 Li W. (2017). “(S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats”. Sci Rep. 7(1):10052. doi: 10.1038/s41598-017-10283-4. PMID: 28855592.